Lecturer Yousef Farhad Mirzaei from the Department of Medical Biochemical Analysis at Cihan University-Erbil published a research article entitled “Clinical Perspective: Antibody-Drug Conjugates (ADCs) for the Treatment of HER2-Positive Breast Cancer” in the Molecular Therapy
About the author:
Name: Yousef Farhad Mirzaei
Academic rank: Lecturer
Affiliation: Department of Medical Biochemical Analysis at Cihan University-Erbil.
Google Scholar Account: https://scholar.google.com/citations?user=UCSgv-YAAAAJ&hl=en
ORCID account: https://orcid.org/0000-0002-0160-2412
Title: Molecular Therapy
Science Citation Index: https://mjl.clarivate.com:/search-results?issn=1525-0016&hide_exact_match_fl=true&utm_source=mjl&utm_medium=share-by-link&utm_campaign=search-results-share-this-journal
Science Citation Index Expanded
Clarivate Analytics (Wos: IF =12.9)
Country: United Kingdom
Antibody-drug conjugates (ADCs) are a promising class of cancer biopharmaceuticals that exploit the specificity of a monoclonal antibody (mAb) to selectively deliver highly cytotoxic small molecules to targeted cancer cells, leading to an enhanced therapeutic index through increased antitumor activity and decreased off-target toxicity. ADCs hold a great promise for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after the approval and tremendous success of trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), representing a turning point in both HER2-positive breast cancer treatment and ADC technology. Additionally and importantly, a total of 29 ADC candidates are now being investigated in different stages of clinical development for the treatment of HER2-positive breast cancer. The purpose of this review is to provide an insight into the ADC field in cancer treatment and present a comprehensive overview of ADCs approved or under clinical investigation for the treatment of HER2-positive breast cancer.